

Ambulatory Care Pharmacy Specialty Recertification Literature Study
Module 1B: Hot Topics in Diabetes

Learning Objectives and Articles

Module 1B: Hot Topics in Diabetes

ACPE Number: 0204-9999-20-970-H01-P

Credit Hours: 4

This module focuses on hot topics in diabetes management, including the SGLT-2 inhibitors in cardiovascular and renal outcomes, as well as diabetes and heart failure.

Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med.* 2019; 380:2295-2306. DOI: 10.1056/NEJMoa1811744.

Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study.
- Develop recommendations for the use of canagliflozin in patients with type 2 diabetes mellitus and albuminuric chronic kidney disease.

McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019; DOI: 10.1056/NEJMoa1911303.

Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study of dapagliflozin in patients with heart failure and reduced ejection fraction with or without type 2 diabetes mellitus.
- Develop recommendations for the use of dapagliflozin in adults with heart failure and reduced ejection fraction with or without type 2 diabetes mellitus.

Dunlay SM, Givertz MM, Aguilar D et al. AHA Scientific Statement: Type 2 Diabetes Mellitus and Heart Failure. *Circulation.* 2019; 139:e1-e31.

<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000006913>.

Learning Objectives:

- Describe the epidemiology, pathophysiology, and impact of type 2 diabetes mellitus and its control on outcomes in patients with heart failure, and outline approaches to pharmacotherapy and lifestyle modification in patients with type 2 diabetes mellitus and at high risk for or with heart failure in the American Heart Association (AHA) and Heart Failure Society of America (HFSA) joint scientific statement on these conditions.

- Develop recommendations for pharmacotherapy and lifestyle modification in patients with type 2 diabetes mellitus and at high risk for or with heart failure.

Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2019; 380:347-57.

Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) study of a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with type 2 diabetes mellitus and established or multiple risk factors for atherosclerotic cardiovascular disease.
- Develop recommendations for the use of dapagliflozin in patients with type 2 diabetes mellitus and established or multiple risk factors for atherosclerotic cardiovascular disease.